in the forward-looking statements
for various reasons, including, but not limited to the Company's ability to
fund development of its technology, ability to establish and successfully
complete clinical trials and pre-clinical studies and the results of those
trials and studies, dependence on its partners for certain development
activities, need for regulatory approvals and commercial acceptance of its
products, ability to recommence marketing and gain commercial acceptance of
NeutroSpec(R), ability to protect its intellectual property, and other
factors discussed in the Company's periodic filings with the Securities and
Exchange Commission. The Company is not responsible for updating for events
that occur after the date of this press release.
PALATIN TECHNOLOGIES, INC.
Consolidated Statements of Operations
(unaudited)
Three Months Ended Nine Months Ended
March 31, March 31,
2008 2007 2008 2007
REVENUES:
Licenses, grants
and contracts $746,957 $3,090,036 $10,467,523 $11,768,247
OPERATING EXPENSES:
Research and
development 4,561,047 8,128,584 16,296,268 29,821,764
General and
administrative 1,480,167 2,021,734 5,468,229 5,239,142
Total operating
expenses 6,041,214 10,150,318 21,764,497 35,060,906
Loss from operations (5,294,257) (7,060,282) (11,296,974) (23,292,659)
OTHER INCOME (EXPENSE):
Investment income 197,199 348,337 908,290 899,711
Interest expense (14,136) (9,223) (44,834) (32,411)
Total other income,
net 183,063 339,114 863,456 867,300
'/>"/>SOURCE Palatin Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th2.
Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure3.
Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th4.
Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 20075.
Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 20076.
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 20077.
Palatin Technologies Refutes Competitive Technologies Contention of Material Breach8.
Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program9.
Veran Medical Technologies Secures $4.75M in First Institutional Funding10.
Neurobiological Technologies Reports Third Quarter Financial Results11.
InSet Technologies Appoints Jon Tremmel to its Board of Directors